Marcel Nijland

30PUBLICATIONS
134CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Haematological tumoursPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Mar 17, 2026
Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Leon D Kaulen, Lakshmi Nayak, Philipp Karschnia

|Feb 04, 2026
Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study.

Floriske G Stedema, Mirian Brink, Francien Huisman

|Dec 18, 2025
Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.

Yujie Zhong, Johanna Bult, Nick Veltmaat

|Dec 12, 2025
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.

Steven Wang, Marcel Nijland, Leonie Strobbe

|Sep 08, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi, Anna Sureda, Sirpa Leppä

Pageof 5

Frequent Collaborators

12 joint publications

Joost Sp Vermaat

10 joint publications

Arjan Diepstra

9 joint publications

Anke van den Berg

8 joint publications

Mirian Brink